Collaborative Arrangements - Parion Sciences, Inc. (Details) - USD ($)
|
1 Months Ended |
3 Months Ended |
12 Months Ended |
Dec. 31, 2018 |
Dec. 31, 2019 |
Sep. 30, 2019 |
Jun. 30, 2019 |
Mar. 31, 2019 |
Dec. 31, 2018 |
Sep. 30, 2018 |
Jun. 30, 2018 |
Mar. 31, 2018 |
Sep. 30, 2017 |
Dec. 31, 2019 |
Dec. 31, 2018 |
Dec. 31, 2017 |
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Provision for (benefit from) income taxes |
|
$ 93,716,000
|
$ 13,148,000
|
$ 59,711,000
|
$ 51,534,000
|
$ (1,492,599,000)
|
$ 8,055,000
|
$ 10,341,000
|
$ (12,659,000)
|
|
$ 218,109,000
|
$ (1,486,862,000)
|
$ (107,324,000)
|
| Intangible asset impairment charges |
|
|
|
|
|
$ 29,000,000
|
$ 0
|
$ 0
|
$ 0
|
|
0
|
29,000,000
|
255,340,000
|
| (Increase) decrease in fair value of contingent payments |
|
$ (1,500,000)
|
$ (2,959,000)
|
$ 0
|
$ 0
|
|
|
|
|
|
$ (4,459,000)
|
0
|
0
|
| Parion Sciences, Inc |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Provision for (benefit from) income taxes |
|
|
|
|
|
|
|
|
|
$ (126,200,000)
|
|
|
|
| (Increase) decrease in fair value of contingent payments |
|
|
|
|
|
|
|
|
|
69,600,000
|
|
|
|
| Income tax expense (benefit), attributable to intangible asset impairment |
|
|
|
|
|
|
|
|
|
(97,700,000)
|
|
|
|
| Income tax expense (benefit), attributable to decrease in the fair value of contingent consideration liability |
|
|
|
|
|
|
|
|
|
(28,500,000)
|
|
|
|
| Deconsolidation,loss, amount |
|
|
|
|
|
|
|
|
|
|
|
|
7,100,000
|
| Variable Interest Entity, Primary Beneficiary |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Provision for (benefit from) income taxes |
|
|
|
|
|
|
|
|
|
|
|
(3,668,000)
|
(114,090,000)
|
| (Increase) decrease in fair value of contingent payments |
|
|
|
|
|
|
|
|
|
|
|
(17,730,000)
|
62,560,000
|
| Variable Interest Entity, Primary Beneficiary | Parion Sciences, Inc |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Collaborative and royalty revenues |
|
|
|
|
|
|
|
|
|
|
|
|
40,000,000.0
|
| Provision for (benefit from) income taxes |
|
|
|
|
|
|
|
|
|
|
|
|
14,800,000
|
| Fair value of intangible asset |
|
|
|
|
|
|
|
|
|
255,300,000
|
|
|
|
| Other Intangible Assets | Variable Interest Entity, Primary Beneficiary | Parion Sciences, Inc |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Intangible asset impairment charges |
|
|
|
|
|
|
|
|
|
255,300,000
|
|
|
255,300,000
|
| Fair value of intangible asset |
|
|
|
|
|
|
|
|
|
$ 0
|
|
|
|
| Other Intangible Assets | Variable Interest Entity, Primary Beneficiary | BioAxone Biosciences, Inc |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Intangible asset impairment charges |
$ 29,000,000.0
|
|
|
|
|
|
|
|
|
|
|
$ 29,000,000.0
|
$ 29,000,000
|